Фьючерсы
Доступ к сотням фьючерсов
TradFi
Золото
Одна платформа мировых активов
Опционы
Hot
Торги опционами Vanilla в европейском стиле
Единый счет
Увеличьте эффективность вашего капитала
Демо-торговля
Введение в торговлю фьючерсами
Подготовьтесь к торговле фьючерсами
Фьючерсные события
Получайте награды в событиях
Демо-торговля
Используйте виртуальные средства для торговли без риска
Запуск
CandyDrop
Собирайте конфеты, чтобы заработать аирдропы
Launchpool
Быстрый стейкинг, заработайте потенциальные новые токены
HODLer Airdrop
Удерживайте GT и получайте огромные аирдропы бесплатно
Launchpad
Будьте готовы к следующему крупному токен-проекту
Alpha Points
Торгуйте и получайте аирдропы
Фьючерсные баллы
Зарабатывайте баллы и получайте награды аирдропа
Инвестиции
Simple Earn
Зарабатывайте проценты с помощью неиспользуемых токенов
Автоинвест.
Автоинвестиции на регулярной основе.
Бивалютные инвестиции
Доход от волатильности рынка
Мягкий стейкинг
Получайте вознаграждения с помощью гибкого стейкинга
Криптозаймы
0 Fees
Заложите одну криптовалюту, чтобы занять другую
Центр кредитования
Единый центр кредитования
DeFi Researcher Questions Injective Protocol's Appeal: Is INJ Overvalued?
Thor Hartvigsen, a data-driven decentralized finance (DeFi) researcher, is questioning the appeal of Injective Protocol, a layer-1 platform whose creators say is designed to expressly power finance.
As of December 2023, INJ, the native currency of Injective Protocol, is one of the top-performing coins, surpassing Bitcoin (BTC) and Ethereum (ETH).
Is Injective Protocol Undervalued Based On On-Chain Metrics?
Taking to X on December 14, Hartvigsen highlighted the platform’s relatively low total value locked (TVL) of $11 million and the limited number of protocols launched on the platform, currently standing at seven.
Based on the researcher’s analysis, the largest dapp on the layer-1, Helix Protocol, a decentralized exchange (DEX), only manages a daily trading volume of about $7.4 million
So far, looking at data, there are only seven active protocols on Injective, with Helix managing over 60% of the eco’s TVL, reinforcing its dominance.
If on-chain activity and the number of active protocol leads, Hartvigsen wants answers to irrefutably justify Injective Protocol’s $3.2 billion valuation.
The researcher compares Injective with other blockchains, including Ethereum and Solana. These platforms command relatively higher trading volume and on-chain activity
On the other hand, Solana, a competing layer-1, presently processes between $500 and $700 million. Meanwhile, Injective Protocol cannot match Ethereum, which processes over $1 billion in trading volume.
INJ Up 395%, Will Prices Continue Rising On Investor Optimism?
In response to Hartvigsen’s analysis, yiggit, a user claiming to be a legal counsel, defended Injective Protocol. The user emphasized that TVL, as the researcher cited, cannot be the sole determinant to gauge a project’s potential
Related Reading: Bitcoin Deja Vu: Capital Inflows Mirror Pre-2021 Bull Run Momentum
Yiggit added that Injective Protocol’s potential is rooted in the expected number of upcoming apps. Notably, the legal counsel notes that optimism also stems from the Injective Protocol’s origins in Cosmos. In the Cosmos eco, staking tends to catalyze participation as users seek to receive airdrops.
Still, whether or not the researcher’s assessment is valid depends on time. So far, looking at the INJ price action in the daily chart, the coin has been charting higher, registering new all-time highs.
To illustrate, INJ is up 395% from mid-October 2023, rallying as the broader crypto market recovers. At this valuation, CoinMarketCap data shows that the project has a market cap of over $2.7 billion.
Disclaimer: The article is provided for educational purposes only. It does not represent the opinions of NewsBTC on whether to buy, sell or hold any investments and naturally investing carries risks. You are advised to conduct your own research before making any investment decisions. Use information provided on this website entirely at your own risk.